UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2025
Commission
File Number: 001-42527
Basel
Medical Group Ltd
6
Napier Road,
Unit
#02-10/11 Gleneagles Medical Centre
Singapore
258499
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Appointment
of Chief Commercial Officer
The
Board of Directors of Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) has appointed Mr. Tan Boon Chye (Darren) as
its Chief Commercial Officer effective August 15, 2025.
Mr.
Darren Tan began his entrepreneurial journey in 2007 with a marketing venture. With extensive experience in business consulting, marketing,
financing, and corporate development, he has a proven track record in business. A graduate of the University of London (BSc Accounting
& Finance), Darren has also co-founded multiple companies across diverse industries. His achievements have been recognized with the
2010 Successful Entrepreneur Award (Platinum Category) and the 2011 SME1 Asia Emerging Award, and he has been featured by Global Business
Magazine, Channel News Asia, and Phoenix Satellite TV.
Mr.
Darren Tan is an equity interest holder in Basel Medical Fund, a subfund of Rainforest Capital VCC, which is the majority and controlling
shareholder of the Company. No family relationship exists between Mr. Darren Tan and any other director or executive officer of the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Basel
Medical Group Ltd |
| |
|
|
| |
By: |
/s/
Darren Yen Feng Chhoa |
| |
Name: |
Dr.
Darren Yen Feng Chhoa |
| |
Title: |
Chief
Executive Officer |
| |
|
|
| Date:
August 21, 2025 |
|
|
